✨ Free AI Report
Mersana Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Mersana Therapeutics, Inc.
Research Preview

Mersana Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs). As of January 6, 2026, Mersana's common stock ceased trading on Nasdaq and was de...

Analyst-debate audio for Mersana Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Mersana Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Mersana Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
4/ 10Mixed

Cyborg Score thesis

Acquired for its novel B7-H4-targeting ADC pipeline addressing unmet oncology needs, particularly adenoid cystic...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Oncology / Antibody-Drug Conjugates (ADCs)
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: June 15, 2026
AI-Verified Research
30+ Page Report

Get the Latest Mersana Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Mersana Therapeutics, Inc. Overview

Pro stress-test →

Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs). As of January 6, 2026, Mersana's common stock ceased trading on Nasdaq and was delisted following Day One Biopharmaceuticals' successful acquisition of Mersana Therapeutics.

Strategic Profile

Pro stress-test →

The company developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that generated a pipeline of wholly-owned and partnered product candidates with potential to treat a range of cancers. The company had strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates.

Competitive Landscape

Pro stress-test →

Mersana competed in the ADC oncology space against specialized developers like Sutro Biopharma, CytomX Therapeutics, and MacroGenics. The company differentiated through proprietary Dolasynthen and Immunosynthen platforms designed for dual payload delivery mechanisms. However, ADC development is dominated by larger pharma players and specialized biotech with more advanced clinical programs.

Industry Context

Mersana Therapeutics, Inc. operates in Biopharmaceutical - Oncology / Antibody-Drug Conjugates (ADCs).

Key facts

Founded: 2001 · Headquarters: Cambridge, Massachusetts, USA

What the analysts stress-tested

The top findings that survived the multi-agent debate for Mersana Therapeutics, Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Mersana Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Sutro BiopharmaADC-focused biotech with protein design platform→CytomX TherapeuticsProbody ADC technology platform for oncology→MacroGenicsImmunotherapeutic and ADC pipeline for cancer→

Compare Mersana Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Mersana Therapeutics, Inc. operates in Biopharmaceutical - Oncology / Antibody-Drug Conjugates (ADCs). See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Oncology / Antibody-Drug Conjugates (ADCs) research →
NEW · MCP server

Ask your AI assistant about Mersana Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Mersana Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Mersana Therapeutics, Inc. do this quarter?”
“Is Mersana Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Mersana Therapeutics, Inc. do?+
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs). As of January 6, 2026, Mersana's common stock ceased trading on Nasdaq and was de...
What is Mersana Therapeutics, Inc.'s Cyborg Score?+
Mersana Therapeutics, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Mersana Therapeutics, Inc.'s main competitors?+
Named competitors include Sutro Biopharma, CytomX Therapeutics, MacroGenics. The full competitive landscape is in the AskCyborg report.
How can I get the full Mersana Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Mersana Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Mersana Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9Anthropic9Dubai Electricity and Water Authority (DEWA)9Emaar Development PJSC9Gold Fields Limited9Western Digital Corporation9Advantest Corporation9Fast Retailing Co., Ltd.9JPMorgan Chase & Co.9Siemens AG9Space Exploration Technologies Corp8Arcellx, Inc.8Gentili Mosconi S.p.A.8Neurogene Inc.8Selvaag Bolig ASA8Satellogic Inc.8Klaveness Combination Carriers ASA8Unusual Machines, Inc.8Shoei Co., Ltd.